When analyzing antibody responses in IBD patients in relation to their treatment regimens, only patients receiving TNF-α inhibitors exhibited lower antibody levels, but not those treated with integrin antagonist vedolizumab or the anti-IL-12/23 ustekinumab, which adds to a previous publication showing reduced GMTs in infliximab-treated patients compared to vedolizumab (28, 29). This evidence concerns the gene TNF and inflammatory bowel disease.